Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comDescription:
The gastrin-releasing peptide receptor (GRPR), also known as bombesin receptor subtype II (BB2), is a member of the G protein-coupled receptor family of bombesin receptors. GRPR is over-expressed in various types of human tumors. RM26, a GRPR antagonist with high affinity, was discovered by peptide backbone modification of bombesin analogues. To target gastrin-releasing peptide receptor in human neoplastic cells NOTA-PEG2-RM26 was synthesised and then labeled with 68Ga. An open-label whole-body PET/ CT study was designed to investigate the safety and dosimetry of 68Ga-NOTA-PEG2-RM26 and to assess its clinical diagnostic value in patients with cancer.
Sponsor:
Karolinska University HospitalPhase:
Phase 1
Contacts:
Antonios Tzortzakakis, MD, PhDantonios.tzortzakakis@regionstockholm.se
08-123 70 000
Annette Fransson-Andreo-Hernandez, PhDannette.fransson-andreo-hernandez@regionstockholm.se
+468 517 753 74
Government Study Link:
NCT06147362 - Click here to see study onClinicalTrials.gov
Help us improve your experience